Shots:
- The LANDSCAPE and NEST clinical development program evaluates the efficacy and safety of zuranolone in patients with MDD and PPD. The presentations also include data from the P-III WATERFALL & open-label SHORELINE study for MDD
- The studies showed a reduction in depressive symptoms including improvements in depressive moods & rapid onset of significant effect @3 day. The therapy showed a consistent safety profile in the totality of clinical data
- In pooled analyses from the LANDSCAPE and NEST programs of SF-36v2, the therapy showed a rapid improvement in QoL, functioning, and well-being domains @15 day and across all domains @42 day
Click here to read full press release/ article | Ref: Biogen | Image: Stat News
The post Sage and Biogen Present Results of Zuranolone in LANDSCAPE and NEST Clinical Development Programs for the Treatment of MDD and PPD at ECNP 2021 first appeared on PharmaShots.
